Industry Briefs

Biotech Wins Some, Loses Some State legislators throughout the country have started looking at biotechnology—and the results, according to one survey, have been positive for scientists. The Industrial Biotechnology Association (IBA) finds 51 legislative initiatives either pending or enacted in 24 states. In a flurry of lawmaking, five of the 51 bills were enacted this past March. Richard Godown, the IBA president, says he was pleasantly surprised by the survey’s results. “At

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

State legislators throughout the country have started looking at biotechnology—and the results, according to one survey, have been positive for scientists. The Industrial Biotechnology Association (IBA) finds 51 legislative initiatives either pending or enacted in 24 states. In a flurry of lawmaking, five of the 51 bills were enacted this past March. Richard Godown, the IBA president, says he was pleasantly surprised by the survey’s results. “At first my attention was drawn by those laws that were restrictive,” like the proposed Wisconsin statute that sought a ban on the BST bovine growth hormone; Godown calls the proposed law “antediluvian stupidity.” The survey, however, showed that most of the bills introduced into the state legislatures were “directed toward attracting biotechnology.” In fact, while rejecting the BST ban, the Wisconsin legislature passed another biotech law, offering guidelines for the release into the environment of genetically engineered organisms, that Godown calls “the model ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies